Ilaris Gout Review Reflects Tougher FDA Approach To Biologic Dosing Safety
Executive Summary
FDA’s review of Novartis’ sBLA for Ilaris (canakinumab) in gout reflects an evolving agency philosophy toward dose optimization for biologic agents – an approach that is likely to require more sponsor attention to pre-approval dose exploration studies.
You may also be interested in...
Novartis Takes Stock Of Ilaris For Gout Following FDA's Complete Response Letter
The agency seeks more clinical data on canakinumab in refractory patients after an advisory committee meeting that focused on the drug's potential risks.
Novartis Takes Stock Of Ilaris For Gout Following FDA's Complete Response Letter
The agency seeks more clinical data on canakinumab in refractory patients after an advisory committee meeting that focused on the drug's potential risks.
Ilaris Diabetes, Cardiovascular Trials Are Unethical, Public Citizen Says
Group says there is no preliminary evidence to suggest the drug would be beneficial for these indications.